Regulatory procedures for obtaining marketing authorization of medicines in the European Union are described. There are several types of authorization procedures including the centralised procedure, mutual recognition procedure, and decentralized procedure. Conditional approval may be granted if the risk-benefit balance is positive, comprehensive data will likely be provided, and unmet medical needs will be fulfilled. Accelerated assessment can be requested for products that are major therapeutic innovations or of major public health interest. Compassionate use programs make products available for named patients or cohorts when a product has not yet received full authorization.
This presentation contains information about dossier preparation and submission as well as about CTD (Common Technical Document) which is an internationally agreed format for the preparation of applications regarding new drugs intended to be submitted to regional regulatory authorities in participating countries.
This presentation contains information about dossier preparation and submission as well as about CTD (Common Technical Document) which is an internationally agreed format for the preparation of applications regarding new drugs intended to be submitted to regional regulatory authorities in participating countries.
Regulatory Approval Process for Medical Devices in EU - Presentation by Aksha...Akshay Anand
A presentation on Regulatory Approval Process for Medical Devices in European Union that explains in brief about the various aspects including the EU Medical Device Directives, Classifications, CE Certification, Medical Device Registration & Timelines. This was presented as a part of curriculum by Akshay Anand in JSS College of Pharmacy, Mysuru during January 2015
What is a Variation…?
Variation regulations and guidelines
Types of variations
Type-IA
Type-IB
Type-II
Extension
Unforeseen variations (Z category)
Grouping of variations
Work sharing of variations
Fee
eAF
Renewals
PAREXEL Principal Consultant Angela McGillivary discusses commercial considerations, clinical development, regulatory requirements, submission and post approval strategies in emerging markets
The document filing for a pharmaceutical product is done in the form of dossier. The slides explain the format and content to be included in all the formats of dossiers.
COMMON REGULATORY AFFAIRS JOB INTERVIEW QUESTIONS WITH ANSWERS-Updated in 2022!Pristyn Research Solutions
COMMON REGULATORY AFFAIRS
JOB INTERVIEW QUESTIONS WITH
ANSWERS By Pristyn Research-Updated 2022.
A quick Job interview short guide For Pharma and all
Life science jobseekers.
info.pristynresearch.com
www.pristynresearch.com
9028839789 | 8999717656
All Medical | Biotech |Micro |B.Sc., M.Sc.
PAN India DRA companies
list alphabetically
This presentation provides an overview of proposals for implementation of several reform initiatives relevant to prescription medicines, including expedited pathways for registration, enhanced post-market monitoring, variations to registered medicines, work sharing with comparable overseas regulators, the use of overseas assessment reports, and reforms to the orphan drug programs. The information session was held ahead of formal public consultations to provide an early view of the reform proposals to those stakeholders who will be most directly involved in the design of the new regulatory arrangements.
Regulatory Approval Process for Medical Devices in EU - Presentation by Aksha...Akshay Anand
A presentation on Regulatory Approval Process for Medical Devices in European Union that explains in brief about the various aspects including the EU Medical Device Directives, Classifications, CE Certification, Medical Device Registration & Timelines. This was presented as a part of curriculum by Akshay Anand in JSS College of Pharmacy, Mysuru during January 2015
What is a Variation…?
Variation regulations and guidelines
Types of variations
Type-IA
Type-IB
Type-II
Extension
Unforeseen variations (Z category)
Grouping of variations
Work sharing of variations
Fee
eAF
Renewals
PAREXEL Principal Consultant Angela McGillivary discusses commercial considerations, clinical development, regulatory requirements, submission and post approval strategies in emerging markets
The document filing for a pharmaceutical product is done in the form of dossier. The slides explain the format and content to be included in all the formats of dossiers.
COMMON REGULATORY AFFAIRS JOB INTERVIEW QUESTIONS WITH ANSWERS-Updated in 2022!Pristyn Research Solutions
COMMON REGULATORY AFFAIRS
JOB INTERVIEW QUESTIONS WITH
ANSWERS By Pristyn Research-Updated 2022.
A quick Job interview short guide For Pharma and all
Life science jobseekers.
info.pristynresearch.com
www.pristynresearch.com
9028839789 | 8999717656
All Medical | Biotech |Micro |B.Sc., M.Sc.
PAN India DRA companies
list alphabetically
This presentation provides an overview of proposals for implementation of several reform initiatives relevant to prescription medicines, including expedited pathways for registration, enhanced post-market monitoring, variations to registered medicines, work sharing with comparable overseas regulators, the use of overseas assessment reports, and reforms to the orphan drug programs. The information session was held ahead of formal public consultations to provide an early view of the reform proposals to those stakeholders who will be most directly involved in the design of the new regulatory arrangements.
Expert review of medicines and medical devices regulation: Prescription medic...TGA Australia
This presentation outlines proposals for implementation of several recommendations from the Review of Medicines and Medical Devices Regulation relevant to prescription medicines, including expedited pathways for registration, enhanced post-market monitoring, variations to registered medicines, work sharing with comparable overseas regulators, and the use of overseas assessment reports.
Medicinal products are highly regulated in the European Union (EU) and are subject to a separate, complicated system of approvals that governs how, when, where, and in what form such products will be allowed to be sold within the borders of the EU.
Pharmaceutical regulatory systems in the EU comprise a decentralized body called the European Medicines Agency (EMA), Heads of Medicines Agencies (HMA), National Competent Authorities (NCAs) and European Directorate for the Quality of Medicines (EDQM). and collection of rules and regulations governing medicinal products in the EU is Eudralex.
The European Medicines Evaluation Agency (EMEA) was established in London, in the year 1995, to coordinate the European Union (EU) member states for evaluating and controlling the medicinal products for both human and veterinary use
The European medicines regulatory system is based on a network of around 50 regulatory authorities from the 31 EEA countries (28 EU Member States plus Iceland, Liechtenstein and Norway)
EMA is responsible for the scientific evaluation, essentially of innovative and high-technology medicines developed by pharmaceutical companies for use in the EU.
EMA has various committees for various categories of medicinal products
Committee for Medicinal Products for Human Use (CHMP)
Pharmacovigilance Risk Assessment Committee (PRAC)
Committee for Medicinal Products for Veterinary Use (CMVP)
Committee for Orphan Medicinal Products (COMP)
Committee on Herbal Medicinal Products (HMPC)
Committee for Advanced Therapies (CAT)
Paediatric Committee (PDCO)
For a medicinal product to seek market authorization in Europe, the manufacturer or sponsor shall choose a pathway from four different pathways based upon the type of medicinal substance, and requirements such as a number of countries chosen for marketing, timeline, etc.
Biotechnology trends are explored in this presentation with a basic overview of laboratory procedures widely used in biotechnology, molecular genetics, immunology, and biochemistry. These are discussed in the context of broadly stated research objectives, the emphasis on applications and strategies rather than techniques and looking at what is influencing trends in Australia and overseas in areas covering cell biology, DNA, genes, mutations, proteins, RNA, plasmids, genetic engineering, biosimilars, stem cells, proteomics, antibodies, drug discovery, and drug development.
Presentation: Spotlight on prescription medicines reformsTGA Australia
An overview of initiatives arising from the Review of Medicines and Medical Devices Regulation relevant to prescription medicines as well as orphan drugs and developments for eCTD and the new MedSearch app.
TGA presentation: Provisional approval pathway for prescription medicinesTGA Australia
This presentation provided an overview of some of the reform activities relevant to prescription, OTC and complementary medicines and implementation of recommendations from the Review of Medicines and Medical Devices Regulation including the content of the consultations on enhancements
201 regulatory aspects of drug and cosmetics .pdfBhavikaAPatel
regulatory aspects of drug and cosmetics
1. Regulatory Requirements for Registration of Drugs & Post Approval Requirements in WHO through Prequalification Program
2. FDA ORGANIZATION CHART
3. Marketing Authorization of EU for APPLICATION PROCEDURES
4. Global Countries Classification
5. Organization and structure of EMA&EDQMActive substance Master files IMPD
6. DRUG MASTER FILE in USA
TGA Presentation: What’s happening in regulation?TGA Australia
This presentation provides an overview of the Government's response to the Expert Panel Review of Medicines and Medical Devices, with an emphasis on complementary medicines changes.
TGA presentation: AusMedtech, 24 May 2017 TGA Australia
This presentation outlines reforms to the device regulatory system following the Expert Panel Review of Medicines and Medical Devices Regulation, reforms to the in vitro diagnostic devices (IVD) regulatory framework, reforms to the European and IVD system and the TGA's new Clinical Evidence Guidelines.
TGA Presentation: TGA’s Role in Clinical Trials Regulation and AdministrationTGA Australia
An overview of supplying ‘unapproved’ therapeutic goods in clinical trials, Clinical Trial Notification (CTN) and Clinical Trial Exemption (CTX) Schemes, TGA and Stakeholders Responsibilities, Safety reporting and other regulatory requirements, Clinical trials FAQs, and the Australian Clinical Trials Handbook update
The French Revolution, which began in 1789, was a period of radical social and political upheaval in France. It marked the decline of absolute monarchies, the rise of secular and democratic republics, and the eventual rise of Napoleon Bonaparte. This revolutionary period is crucial in understanding the transition from feudalism to modernity in Europe.
For more information, visit-www.vavaclasses.com
2024.06.01 Introducing a competency framework for languag learning materials ...Sandy Millin
http://sandymillin.wordpress.com/iateflwebinar2024
Published classroom materials form the basis of syllabuses, drive teacher professional development, and have a potentially huge influence on learners, teachers and education systems. All teachers also create their own materials, whether a few sentences on a blackboard, a highly-structured fully-realised online course, or anything in between. Despite this, the knowledge and skills needed to create effective language learning materials are rarely part of teacher training, and are mostly learnt by trial and error.
Knowledge and skills frameworks, generally called competency frameworks, for ELT teachers, trainers and managers have existed for a few years now. However, until I created one for my MA dissertation, there wasn’t one drawing together what we need to know and do to be able to effectively produce language learning materials.
This webinar will introduce you to my framework, highlighting the key competencies I identified from my research. It will also show how anybody involved in language teaching (any language, not just English!), teacher training, managing schools or developing language learning materials can benefit from using the framework.
Introduction to AI for Nonprofits with Tapp NetworkTechSoup
Dive into the world of AI! Experts Jon Hill and Tareq Monaur will guide you through AI's role in enhancing nonprofit websites and basic marketing strategies, making it easy to understand and apply.
The Roman Empire A Historical Colossus.pdfkaushalkr1407
The Roman Empire, a vast and enduring power, stands as one of history's most remarkable civilizations, leaving an indelible imprint on the world. It emerged from the Roman Republic, transitioning into an imperial powerhouse under the leadership of Augustus Caesar in 27 BCE. This transformation marked the beginning of an era defined by unprecedented territorial expansion, architectural marvels, and profound cultural influence.
The empire's roots lie in the city of Rome, founded, according to legend, by Romulus in 753 BCE. Over centuries, Rome evolved from a small settlement to a formidable republic, characterized by a complex political system with elected officials and checks on power. However, internal strife, class conflicts, and military ambitions paved the way for the end of the Republic. Julius Caesar’s dictatorship and subsequent assassination in 44 BCE created a power vacuum, leading to a civil war. Octavian, later Augustus, emerged victorious, heralding the Roman Empire’s birth.
Under Augustus, the empire experienced the Pax Romana, a 200-year period of relative peace and stability. Augustus reformed the military, established efficient administrative systems, and initiated grand construction projects. The empire's borders expanded, encompassing territories from Britain to Egypt and from Spain to the Euphrates. Roman legions, renowned for their discipline and engineering prowess, secured and maintained these vast territories, building roads, fortifications, and cities that facilitated control and integration.
The Roman Empire’s society was hierarchical, with a rigid class system. At the top were the patricians, wealthy elites who held significant political power. Below them were the plebeians, free citizens with limited political influence, and the vast numbers of slaves who formed the backbone of the economy. The family unit was central, governed by the paterfamilias, the male head who held absolute authority.
Culturally, the Romans were eclectic, absorbing and adapting elements from the civilizations they encountered, particularly the Greeks. Roman art, literature, and philosophy reflected this synthesis, creating a rich cultural tapestry. Latin, the Roman language, became the lingua franca of the Western world, influencing numerous modern languages.
Roman architecture and engineering achievements were monumental. They perfected the arch, vault, and dome, constructing enduring structures like the Colosseum, Pantheon, and aqueducts. These engineering marvels not only showcased Roman ingenuity but also served practical purposes, from public entertainment to water supply.
Instructions for Submissions thorugh G- Classroom.pptxJheel Barad
This presentation provides a briefing on how to upload submissions and documents in Google Classroom. It was prepared as part of an orientation for new Sainik School in-service teacher trainees. As a training officer, my goal is to ensure that you are comfortable and proficient with this essential tool for managing assignments and fostering student engagement.
Francesca Gottschalk - How can education support child empowerment.pptxEduSkills OECD
Francesca Gottschalk from the OECD’s Centre for Educational Research and Innovation presents at the Ask an Expert Webinar: How can education support child empowerment?
Operation “Blue Star” is the only event in the history of Independent India where the state went into war with its own people. Even after about 40 years it is not clear if it was culmination of states anger over people of the region, a political game of power or start of dictatorial chapter in the democratic setup.
The people of Punjab felt alienated from main stream due to denial of their just demands during a long democratic struggle since independence. As it happen all over the word, it led to militant struggle with great loss of lives of military, police and civilian personnel. Killing of Indira Gandhi and massacre of innocent Sikhs in Delhi and other India cities was also associated with this movement.
Read| The latest issue of The Challenger is here! We are thrilled to announce that our school paper has qualified for the NATIONAL SCHOOLS PRESS CONFERENCE (NSPC) 2024. Thank you for your unwavering support and trust. Dive into the stories that made us stand out!
How to Make a Field invisible in Odoo 17Celine George
It is possible to hide or invisible some fields in odoo. Commonly using “invisible” attribute in the field definition to invisible the fields. This slide will show how to make a field invisible in odoo 17.
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdfTechSoup
In this webinar you will learn how your organization can access TechSoup's wide variety of product discount and donation programs. From hardware to software, we'll give you a tour of the tools available to help your nonprofit with productivity, collaboration, financial management, donor tracking, security, and more.
4. 4
A medicinal product may only be placed on the market in the
European Economic Area (EEA) when a marketing authorisation
has been issued by the competent authority of that Member State
or by the European Medicines Agency.
The process for obtaining a marketing authorisation is very
detailed and highly regulated.
4 Regulatory Procedures
5. 5 Regulatory Procedures
Scientific Life of a Drug
Assessment based on Quality, Safety and Efficacy
Dossier
Quality
Pre-clinical
Clinical
Summary Product Characteristics (SmPC)
6. 6
6 Regulatory Procedures
Modules of the CTD
1. Specific administrative data including application form,
summary of product characteristics (SmPC), labelling and
package leaflet (PL)
2. Quality overall summary, non-clinical overview/summaries
and clinical overview/summaries
3. Quality – chemical, pharmaceutical and biological
information
4. Safety (Pharmacology/Toxicology) - non-clinical reports
5. Efficacy - clinical study reports
7. 7
SmPC: The cornerstone between
assessment and information
– The scientific assessment should
evaluate how the SmPC will optimise
the benefits and manage the risks.
– The SmPC is the agreed position on
the medicinal product, as distilled
during the course of the assessment
process, before (and after)
marketing authorisation.
– Detailed information and benefit-risk
assessment is provided in public
assessment report
7
European
Public
Assessment
Report
8. 8 Regulatory Procedures
8
Optimised utilisation of resources
Harmonised scientific opinions
Harmonised information to healthcare
professionals & patients
All Systems allow
Centralised
Procedure
Mutual
Recognition/
Decentralised
Procedure
The European System
National
Procedures
10. 10
• In the EU, a company may submit a single application to the European
Medicines Agency (EMA) for a marketing authorisation (licence) that is
valid simultaneously in all EU Member States, plus Iceland,
Liechtenstein and Norway....the centralised authorisation procedure.
• Each EU Member State has its own national procedures for the
authorisation of medicines that fall outside the scope of the
centralised procedure. Applicants must submit an application to
the competent authority of the Member State.
Regulatory Procedures
11. 11
• In the mutual recognition procedure (MRP), a medicine is first
authorised in one EU Member State, in accordance with the national
procedures of that country. Following this, further marketing
authorisations can be sought from other EU countries in a procedure
whereby the countries concerned agree to recognise the validity of the
original, national marketing authorisation.
• Using the decentralised procedure (DCP), companies may apply for
simultaneous authorisation in more than one EU country of products
that have not yet been authorised in any EU country and that do not
fall within the mandatory scope of the centralised procedure.
Regulatory Procedures
12. 12
EU MA Procedures
CP MRP national
Alle EU-
MS
More
than one
to all
EU MSs
only one
EU MS
DCP
More than
one to all
EU MSs
all EU
MSs
12 Regulatory Procedures
15. 15
Mutual Recognition Procedure - MRP
• This procedure is based on the mutual recognition by CMSs of a
national MA granted by a RMS
• An identical application for mutual recognition is to be submitted to all
concerned member states
• RMS prepares an assessment report or updates any existing one
within 90 days
• Copies of the assessment report are sent to all CMSs, together with
the approved SmPC, package labelling and package leaflet
• CMSs then have 90 days to recognise the decision of the RMS
• National marketing authorisations will be granted within 30 days after
acknowledgement of the agreement
Regulatory Procedures
15
16. 16
Decentralised Procedure - DCP
• The DCP is available for new products which have not yet been
authorised in any EEA country and do not fall within the mandatory
scope of the CP
• One member state acts as the RMS and takes the lead
• Submission of an application in all the Member States involved at the
same time
• RMS prepares an assessment report within 120 days
• CMSs then have 90 days to recognise the decision of the RMS
• National marketing authorisations will be granted within 30 days after
acknowledgement of the agreement
• The product will be nationally authorised in the RMS and each CMS
with a harmonised SmPC, package leaflet and package labelling
Regulatory Procedures
16
17. 17
Types (legal bases) of applications for a
MA
• Stand alone (full) application
• “informed consent” application… piggyback
• Generic application
• “well established use” application
• “Mixed” application
• Hybrid application
• Similar biological product application
• application for “new combination” containing active
substances used in already authorised products
Regulatory Procedures
17
18. 18
Compassionate Use
• Medicinal products must be authorised in order to be marketed
BUT
• Compassionate use programmes are intended to facilitate the availability
to patients of new treatment options under development.
• National compassionate use programmes, making medicinal products
available either on a named patient basis or to cohorts of patients, are
governed by individual Member States legislation.
Regulatory Procedures
21. 21 Regulatory Procedures
Compassionate Use
For unauthorised products, products undergoing clinical trials in the
EU or elsewhere
For products applying through centralised procedure
For groups of patients suffering from a chronically or seriously
debilitating disease or whose disease is considered to be life
threatening, who cannot enter a clinical trial, and who cannot be
treated satisfactorily by an authorised medicinal product
Not a substitute for clinical trials
Not for off-label use
22. 22 Regulatory Procedures
Compassionate Use
According to the current legislation, member states (MS) can request EMA-CHMP
opinion on the conditions for use, and distribution and on the patients targeted for
compassionate use.
In this case, CHMP can adopt an non-binding opinion on member states (add
reference of legislation)
24. 24 Regulatory Procedures
Accelerated Assessment
When a marketing application is submitted for a product:
that is of major interest from the point of view of public health
that is of particular interest from the viewpoint of therapeutic
innovation,
Accelerated assessment procedures should be set up to:
meet the expectations of patients
take account the increasingly rapid progress of science and therapies
for medicinal products of major therapeutic interest,
Accelerated assessment should be requested by the applicant and once
authorisation is granted is subject to certain annually reviewable
conditions.
25. 25 Regulatory Procedures
Accelerated Assessment
• Applicant requests time limit reduction 210 days to 150 days
• Applicant justifies:
Major Public Health Interest….therapeutic innovation
Consider unmet medical needs and available methods
Extent to which product is expected to have a major impact on medical
practice, added value, addressing unmet needs
Outline available evidence
• CHMP decides
• During assessment, standard timeline may be considered (major
objections, long clock-stop, need for Good Manufacturing Practice or
Good Clinical Practice inspections)
31. 31 Regulatory Procedures
Conditional Approval
May be granted where, although comprehensive clinical data have not been
supplied, the following apply:
(a) The risk-benefit balance of the medicinal product, as defined in
Article 1(28a) of Directive 2001/83/EC, is positive
(b) It is likely that comprehensive data can be provided
(c) Unmet medical needs will be fulfilled (no satisfactory methods or
major therapeutic advantage)
(d) Benefits of immediate availability outweigh risks due to additional
data to be provided
32. 32 Regulatory Procedures
Conditional Approval
• When the CHMP has based a positive opinion on data which, while not yet
comprehensive, indicate that the medicine’s benefits outweigh its risks.
• The company is given obligations to fulfil, such as the performance of further
studies.
• The approval is renewed on a yearly basis until all obligations have been
fulfilled, and is then converted from a conditional approval into a normal
approval.
• Conditional approvals can only be granted for medicines that satisfy an
‘unmet medical need’, meaning the medicine is intended to be used for a
disease or condition for which no treatment is readily available, and it is
therefore important that patients have early access to the medicine
concerned.
34. 34 Regulatory Procedures
Obligations of Conditional Approval
• Pharmacovigilance data
• Other required data important for understanding of benefit-risk,
e.g.:
Confirm final clinical outcome for likely surrogate endpoints
Confirm long-term effects
Study effect in subgroups
Confirm results of interim analysis
38. 38 Regulatory Procedures
Exceptional Circumstances
Unable to provide comprehensive data on the efficacy and safety of
the medicine
Indication so rare that cannot reasonably be expected to
provide comprehensive evidence
In the present state of scientific knowledge, comprehensive
information cannot be provided
Contrary to medical ethics to collect such information
Authorisation may be granted subject to certain obligations
Usually evaluation involves external expert groups (to determine
clinical relevance)
39. 39 Regulatory Procedures
Obligations of Exceptional Circumstances
Specific Obligations may include
Complete an identified programme of studies within a
specified period of time
Supply by prescription only and possibly under strict
supervision
Package leaflet will point out that particulars concerning the
product are inadequate in certain respects
45. 45
EMA Workplan
Facilitating Access
Exploring the balance between early approval with limited data and later approval with
more extensive data package
Considering the merits and mechanics of an optional approach to early authorisation of
medicines in a restricted population e.g. based on early information from good
responders. Exploring the broader applicability of ‘staggered’ approvals and preparing
guidance on the applicability of such approaches.
Regulatory Procedures
47. 47
PASS
• A post-authorisation safety study (PASS) is a study that is carried
out after a medicine has been authorised to obtain further
information on a medicine's safety, or to measure the effectiveness
of risk-management measures.
• The European Medicines Agency's Pharmacovigilance Risk
Assessment Committee (PRAC) is responsible for assessing the
protocols of imposed PASSs and for assessing their results.
• The purpose of the information in PASSs is to evaluate the safety
and benefit-risk profile of a medicine and support regulatory
decision-making. They aim to:
• identify, characterise or quantify a safety hazard;
• confirm the safety profile of a medicine, or;
• measure the effectiveness of risk-management measures.
• PASSs can either be clinical trials or non-interventional studies.
Regulatory Procedures
47
48. 48
PASS
PASSs are either imposed or voluntary:
• Marketing-authorisation holders (MAHs) are obliged to carry out
imposed PASSs. These include studies that are a specific
obligation for a marketing authorisation granted under
exceptional circumstances and other studies that the PRAC
requests the company carry out.
• Voluntary PASSs are sponsored or conducted by MAHs on their
own initiative. They include non-imposed studies that are
requested in risk-management plans.
Regulatory Procedures
48
50. 50
PAES
• A post-authorisation efficacy study (PAES) is a study that aims to
clarify the benefits of a medicine on the market including efficacy
in everyday medical practice.
• They aim to address concerns related to the efficacy of a
medicine in certain situations, such as everyday medical
practice, in specific populations, or over time. This type of study
already existed, however, the EU pharmacovigilance legislation
that came into force in July 2012 has extended the legal
framework in which they can be required.
• The aim is to enable regulators to request such studies when
there are important questions about the efficacy of the medicine
that can only be answered once the product is in general use, or
when questions arise in the post-authorisation period.
Regulatory Procedures
50
51. 51
Conclusion
• Several procedures for authorisation
• If “full/usual” authorisation not possible, several options exist
• If drug has public health implications, additional options for
authorisation exist
Regulatory Procedures
51